Nonalcoholic Fatty Liver Disease
📧 Sign up to get email alerts when something new happens for Nonalcoholic Fatty Liver Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-02-23Clinical Trial Update: Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
A clinical trial evaluating guselekumab for shared pathways in psoriasis, psoriatic arthritis, and nonalcoholic fatty liver disease has been…
-
CLINICAL_TRIALS withdrawal · 2025-07-14Clinical Trial Update: Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease [Phase 1, Phase 2]
A clinical trial evaluating the safety and efficacy of Cilostazol for nonalcoholic fatty liver disease has been withdrawn, covering Phase 1 …
-
CLINICAL_TRIALS withdrawal · 2025-06-13Clinical Trial Update: Diabetes Prevention and Education [NA]
The clinical trial update indicates a University of Maryland, Baltimore-sponsored study on diabetes prevention and education has been withdr…
-
CLINICAL_TRIALS withdrawal · 2025-05-15Clinical Trial Update: A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis [Phase 3]
Phase 3 study evaluating denifanstat for metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-06-11Clinical Trial Update: A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria [Phase 1]
BioMarin's BMN-255 Phase 1 trial in hyperoxaluria with nonalcoholic fatty liver disease has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-05-14Clinical Trial Update: A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease [Phase 2]
A Phase 2 randomized, placebo-controlled pilot study evaluating the safety and fecal microbiome changes after oral lyophilized PRIM-DJ2727 i…
-
CLINICAL_TRIALS withdrawal · 2017-04-27Clinical Trial Update: Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment [NA]
A clinical trial evaluating endothelial function in patients with nonalcoholic fatty liver disease and the effect of statin therapy was with…
-
CLINICAL_TRIALS withdrawal · 2016-10-05Clinical Trial Update: Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI [Phase 4]
This clinical trial update reports that the Phase 4 study evaluating the DPP-4 inhibitor sitagliptin for non-alcoholic fatty liver disease i…
-
CLINICAL_TRIALS withdrawal · 2015-08-24Clinical Trial Update: Evaluation of Intestinal Microbiome in Obese Kids
A clinical trial evaluating the intestinal microbiome in obese children has been withdrawn. The study was sponsored by the Medical College o…
-
CLINICAL_TRIALS withdrawal · 2013-10-23Clinical Trial Update: ER Stress in NAFLD [EARLY_Phase 1]
An early-phase 1 trial investigating ER stress in obesity and nonalcoholic fatty liver disease sponsored by Vanderbilt University has been w…